In a patient taking pregabalin (especially >300 mg/day) who develops new tachycardia (≥100 bpm), is pregabalin the likely cause and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pregabalin and Tachycardia

Pregabalin can cause tachycardia, particularly at higher doses (≥300 mg/day), and should be considered a likely culprit when new tachycardia develops in a patient taking this medication, especially in elderly patients or those with pre-existing cardiac conditions.

Evidence for Pregabalin-Induced Tachycardia

The FDA drug label explicitly documents cardiovascular effects of pregabalin, including PR interval prolongation of 3-6 msec at doses ≥300 mg/day 1. While the label does not specifically list tachycardia as a common adverse effect in the standard dosing tables 1, case reports demonstrate clear temporal associations between pregabalin administration and tachycardia development.

A particularly compelling case involved a 92-year-old patient with a history of paroxysmal atrial fibrillation who developed sinus tachycardia followed by atrial fibrillation and congestive heart failure within 15 hours of the first pregabalin dose, with the causality assessed as plausible 2. This case underscores that elderly patients with pre-existing cardiac dysrhythmias are at heightened risk.

Mechanism and Risk Factors

The mechanism of pregabalin-induced tachycardia remains unclear 2, but several factors increase risk:

  • Dose-dependent effect: Higher doses (≥300 mg/day) carry greater risk
  • Advanced age: Elderly patients appear more susceptible 2
  • Pre-existing cardiac conditions: History of arrhythmias or heart disease
  • Overdose/toxicity: One case report documented tachycardia and hypertension after 1000 mg ingestion 3
  • Cardiac conduction effects: Pregabalin can cause second-degree AV block in overdose 4, suggesting broader cardiac effects

Management Algorithm

1. Confirm Pregabalin as the Cause

  • Verify temporal relationship between pregabalin initiation/dose escalation and tachycardia onset
  • Rule out other causes: infection, hyperthyroidism, anemia, dehydration, other medications
  • Check for signs of pregabalin toxicity: altered mental status, confusion, somnolence, ataxia 1

2. Immediate Management Based on Severity

If hemodynamically unstable or symptomatic:

  • Discontinue pregabalin immediately
  • Provide supportive care with cardiac monitoring
  • Consider hemodialysis if severe toxicity (removes ~50% in 4 hours) 1

If hemodynamically stable with mild tachycardia:

  • Reduce pregabalin dose to 300 mg/day or lower (doses >300 mg/day are not consistently more effective and have greater adverse effects) 5
  • Monitor heart rate closely for 48-72 hours
  • If tachycardia persists despite dose reduction, discontinue pregabalin

3. Taper Appropriately

Do not abruptly stop pregabalin due to withdrawal risk. Taper gradually over at least 1 week, monitoring for withdrawal symptoms (anxiety, insomnia, nausea, pain, sweating).

4. Alternative Management

If pregabalin must be discontinued for neuropathic pain:

  • Switch to gabapentin (similar efficacy, different pharmacokinetics, may be better tolerated) 5
  • Consider duloxetine 60 mg daily (first-line alternative) 5
  • Consider tricyclic antidepressants (nortriptyline 25-150 mg/day) if no cardiac contraindications 5

Critical Caveats

Do not restart pregabalin at high doses if tachycardia resolves after discontinuation. If restarting is necessary, begin at 75-150 mg/day and titrate slowly with cardiac monitoring 5.

Exercise particular caution in:

  • Patients >75 years old
  • Those with baseline PR prolongation or taking other PR-prolonging medications 1
  • Patients with history of cardiac arrhythmias 2
  • Those on concurrent opioids or CNS depressants (increased risk of adverse effects) 6

Monitor ECG if continuing pregabalin in patients with cardiac risk factors, as pregabalin can cause both tachycardia and conduction abnormalities 1, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.